Ziccum will now be submitting a formal EoI, together with a new partner, to CEPI’s Call for Proposals for companies developing innovative technologies to improve vaccine thermostability. The partner is a well-established biotech company with novel technology and extensive experience within mRNA vaccine formulation and development.

Ziccum previously communicated (July 21, 2022) that it had decided not to apply for the CEPI funding, not having a relevant partner for the international implementation of manufacturing. Subsequent to that decision, Ziccum has been approached by this biotechnology partner to develop a joint application to improve vaccine thermostability. The CEPI CfP targets manufacturing organizations that can implement thermostable vaccine facilities globally.

Ziccum CEO Ann Gidner: “This is a very good union with a shared commitment to innovation in mRNA vaccines. The expertise and capabilities on our partner’s side are solid, inspiring and exciting. We look forward to completing our application.”

About CEPI: CEPI, the Coalition for Epidemic Preparedness Innovations, funds a wide range of research projects to develop vaccines through donations from public, private, charitable and civil society organizations. CEPI is headquartered in Oslo, Norway.